SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Exelixis, Inc. (EXEL)
An SI Board Since January 2001
Posts SubjectMarks Bans Symbol
930 66 0 EXEL
Emcee:  kinkblot Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
905and this was good for a 17 cent gain today... Well now we know why it was only tejek-3/26/2014
904and this was good for a 17 cent gain today... Exelixis receives approval for COIan@SI-3/25/2014
903seekingalpha.com The year aheadNeil H-1/13/2014
902Clin Cancer Res. 2013 Oct 28. [Epub ahead of print] Phase I safety, pharmacokinscaram(o)uche-12/9/2013
901XL147 and XL765 updates from ASH, please follow bouncing ball..... Message 2927scaram(o)uche-12/8/2013
900daviesbj ?@daviesbj 4h #SUO13 McDermott Genentech PD-L1 Ab Phase1a. RCC resposcaram(o)uche-12/5/2013
899immunotherapyofcancer.org MAP kinase inhibitors stimulate T cell and anti-tumorscaram(o)uche111/22/2013
898:-) Andy Biotech ?@AndyBiotech 4h $EXEL 8-K -> RT @jq1234t: It means Rochscaram(o)uche-11/22/2013
897Can you tell I'm not paying attention? Thanks! Cheers, Tucktuck-11/22/2013
896Phase III trial was launched a year ago. This is expanded testing, the report tscaram(o)uche-11/22/2013
895I haven't followed EXEL for a while. But they partnered XL518 concurrently tuck-11/22/2013
894continuing color re. your (seemingly insightful) comment.... Item 8.01. Other Escaram(o)uche-11/22/2013
893this was good for a loss of 3 cents on the day... 8:56 am Exelixis upgraded to Ian@SI-11/12/2013
892Nice results in ColoRectal cancer using Cabo... (in vitro, pre clinical) PublIan@SI-4/8/2013
891>> Not a bad position to be in to be partnered with a company that alreadyscaram(o)uche-3/17/2013
8904:24PM Exelixis Selects Swedish Orphan Biovitrum AB as COMETRIQ European distribIan@SI-2/21/2013
889Endocrinology. 2013 Feb 5. [Epub ahead of print] Inhibition of PI3K/AKT/mTOR Pscaram(o)uche-2/7/2013
888JPM.... this trial apparently has interesting observations, planning "compascaram(o)uche-1/9/2013
887>> No position in EXEL for me but do keep an eye on them a bit << scaram(o)uche-12/14/2012
886Tuck, immunologists have been buried in delta isoform literature. It's sort scaram(o)uche-12/14/2012
885I'm puzzled, too, but the dual inhibition by IPI-145 of the delta and gamma tuck-12/13/2012
884INFI is behind GILD and going after similar indications as PCYC's BTK ibrutimcbio-12/13/2012
883Please take a look at the five day chart for infi. There's a secondary offerscaram(o)uche-12/13/2012
882cancernetwork.com Cabozantinib Active in Advanced Castration-Resistant ProstateIRWIN JAMES FRANKEL-12/10/2012
881Looks like the label warnings might account for the lack of AH love on approval Ian@SI-11/29/2012
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News